Press releases
- Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
- Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
- Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease
- Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Sage Therapeutics to Participate in Upcoming May Investor Conferences
More ▼
Key statistics
As of last trade SAGE Therapeutics Inc (SG7:FRA) traded at 9.90, 6.02% above its 52-week low of 9.33, set on Jul 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.90 |
---|---|
High | 9.90 |
Low | 9.90 |
Bid | 9.50 |
Offer | 10.00 |
Previous close | 10.18 |
Average volume | 711.00 |
---|---|
Shares outstanding | 60.18m |
Free float | 53.00m |
P/E (TTM) | -- |
Market cap | 650.57m USD |
EPS (TTM) | -8.40 USD |
Data delayed at least 15 minutes, as of Jul 30 2024 07:28 BST.
More ▼